USRetina
USRetina is a Denver-based private healthcare company founded in 2012 that delivers clinical and operational solutions to retina specialty practices across the United States, focusing on drug management, practice efficiency, and regulatory navigation for independent retina specialists.
- Company typePrivate
- Founded2012
- HeadquartersDenver, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What USRetina does
USRetina is a Denver-based private healthcare company founded in 2012 that delivers clinical and operational excellence in retina-vitreous care. The firm serves retina specialty practices across the United States, providing solutions that address the business and operational challenges facing independent retina specialists, including regulatory navigation, drug pricing pressures, inventory management, and practice efficiency. USRetina operates with a small team (11-50 employees) and has raised approximately $9.85M across three funding rounds between 2013 and 2015, suggesting a growth-stage company in a focused clinical vertical.
USRetina's go-to-market appears sales-led, targeting retina specialty practices through dedicated outreach and specialty drug distribution channels. Its value proposition centers on enabling independent retina specialists to maintain practice autonomy while managing regulatory, reimbursement, and operational complexity. Source material associates USRetina's retina offering with a platform spanning drug purchasing and management (Onmark Vision GPO), inventory and practice management technology (Lynx, RetinaOS), revenue intelligence with predictive ML/AI capabilities (Glide Health), and financial analysis tools (Regimen Profiler). However, the URL attribution of these products (mckesson.com) and the McKesson-branded social media profiles suggest these capabilities may be delivered through partnership with McKesson rather than independently owned technology, and the precise ownership of each product warrants clarification in due diligence.
The company is led by co-founder and Chief Medical Officer Sunil Gupta, signaling physician leadership and clinical credibility in the retina specialty. The executive team includes a Chief Financial Officer (Primo Beadling) and Chief Technology Officer (Ravi Nemana). USRetina has positioned itself to capture tailwinds from the introduction of more than 20 biosimilars expected in the U.S. healthcare market over the next decade, the shift to value-based care under CMS payment models such as MIPS, and rising adoption of AI-enabled revenue cycle tools. Revenue mechanics are primarily quote-based with multi-year contracts, and the company operates exclusively in the U.S. market.
USRetina firmographics
Firmographics- Name
- USRetina
- Legal name
- USRetina
- Website
- https://usretina.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- USRetina is a Denver-based private healthcare company founded in 2012 that delivers clinical and operational solutions to retina specialty practices across the United States, focusing on drug management, practice efficiency, and regulatory navigation for independent retina specialists.
- Ownership category
- akta.pro rank
USRetina industry classification
Industry- Product category
- Ophthalmology Specialty Practice Services
- NAICS
- Offices of Optometrists (62132)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Retina & Vitreous Specialists (HLAKAKAE)
- akta.pro secondary industry
- Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN)
Keywords
Where USRetina is headquartered
LocationHeadquarters
- HQ city
- Denver
- HQ country
- United States
- HQ region
- North America
Markets served
USRetina business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Specialty Drug Distribution and Management: McKesson provides comprehensive specialty drug management solutions including distribution, purchasing, and inventory management for retina practices. Revenue is generated through the sale and distribution of specialty drugs and related pharmaceutical products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based pricing for specialty practice solutions |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
USRetina product offering
Product offeringCore offering
USRetina delivers clinical and operational excellence in Retina-Vitreous care benefiting patients. The company supports retina specialty practices with comprehensive solutions including specialty drug distribution and management, group purchasing organization services, inventory management technology, practice management software, revenue cycle intelligence, and value-based care advisory support to enable practices to focus on patient care.
Product overview
This is a platform-plus-modules architecture offering comprehensive retina practice management solutions. The portfolio includes drug management tools (Lynx® for inventory management, Onmark® GPO and Onmark Vision for group purchasing), practice technology solutions (RetinaOS for beyond-inventory management, Glide Health for revenue intelligence with AI capabilities, and Regimen Profiler for financial analysis). The McKesson Retina solutions provide an integrated approach combining drug purchasing and management, advisors and tools, value-based care support, technology solutions, and full-service practice management.
Differentiator
Problem solved
Functional benefit
Products and services
- Specialty Drug Distribution and Management
Companies that use USRetina
Customer profileSegments2 records
Ideal customer profiles1 record
USRetina technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
USRetina partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Centers for Medicare & Medicaid Services (CMS)coreMcKesson supports retina practices in adapting to CMS payment models including Enhancing Oncology Model and Merit-based Incentive Payment System (MIPS). Their advisors help practices navigate CMS regulations and avoid penalties.
Scale indicators3 records
Recent moves5 records
Expansion highlights3 records
USRetina competitors and assessment
Company assessmentDirect peers
- Florida Retina Institute: Independent retina specialty practice group in Florida with multiple physicians and sites. Relevant comparable for high-acuity retina case mix, age-driven patient demographics, and the independent-physician model.
- Retina Consultants of Texas: Large independent retina group with multiple clinical and clinical-research sites across Texas. Comparable for physician recruitment, multi-site specialty practice economics, and clinical-trial revenue models.
- Mid-America Retina Consultants: Independent retina specialty practice in the central U.S., offering vitreoretinal surgery and medical retina services. Closely matches USRetina in physician-owned, single-region operating posture.
- Retina Group of New England: Physician-owned retina specialty practice group operating across multiple New England sites. Comparable in scale, multi-physician operating model, and clinical scope (medical retina plus vitreoretinal surgery).
- Retina Associates of Cleveland: Independent retina specialty group concentrated in a single Midwest metro, similar in scale and operating posture to USRetina. Provides a regional single-market comparable for valuation, payer mix, and physician-recruitment dynamics.
- Palmetto Retina Center: Independent retina specialty practice serving South Carolina. Comparable as a physician-led independent retina group with similar patient demographics, anti-VEGF-heavy treatment mix, and capital structure uncertainty.
- The Retina Institute: Multi-physician retina specialty practice with multiple locations in the Midwest and Mid-South. Directly comparable on clinical service mix, multi-site scaling, and physician-recruitment strategy.
- Austin Retina Associates: Multi-physician independent retina specialty practice serving the Austin metro. Directly comparable in patient mix (AMD, DME, RVO), physician-led governance, and buy-and-bill specialty drug revenue model.
- Retina Vitreous Associates: Multi-physician retina and vitreous specialty practice operating in the Mid-Atlantic. Comparable on multi-site scaling, surgeon-staffed model, and heavy buy-and-bill drug economics.
Broad incumbents
- Retina Consultants of America: A leading multi-state retina specialist platform formed through PE-backed consolidation. Largest U.S. retina platform and the most direct comparability signal for valuation/multiples in this specialty; represents the dominant competitive threat to independent retina practices like USRetina.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
USRetina social profiles
Digital presenceUSRetina financial estimates
Financial estimateRevenue estimate
Valuation estimate
USRetina leadership team
Management profileNumber of profiles
Profiles3 records
USRetina funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
USRetina M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about USRetina
What does USRetina do?
USRetina delivers clinical and operational excellence in Retina-Vitreous care benefiting patients. The company supports retina specialty practices with comprehensive solutions including specialty drug distribution and management, group purchasing organization services, inventory management technology, practice management software, revenue cycle intelligence, and value-based care advisory support to enable practices to focus on patient care.
Is USRetina a public or private company?
USRetina is a private company. It is classified as venture growth investor backed and is currently operating.
When was USRetina founded?
USRetina was founded in 2012. It employs 11 to 50 people.
Where is USRetina based?
USRetina is headquartered in Denver, United States, in the North America region.
How does USRetina make money?
One revenue line is on record: specialty Drug Distribution and Management.
Who are USRetina's main competitors?
Direct peers on record are Florida Retina Institute, Retina Consultants of Texas, Mid-America Retina Consultants, Retina Group of New England, Retina Associates of Cleveland, Palmetto Retina Center, The Retina Institute, Austin Retina Associates and Retina Vitreous Associates. Retina Consultants of America is listed as a broad incumbent.
Does USRetina have an API?
No public API is recorded for USRetina.
What industry is USRetina in?
USRetina's product category is Ophthalmology Specialty Practice Services. Its primary akta.pro industry code is HLAKAKAE, Retina & Vitreous Specialists, with a secondary code of HLAKAKAN, Ocular Imaging & Diagnostic Testing Centers. Its NAICS code is 62132 and its SIC code is 8011.